Table 1 Phenotypic features of clinical isolates.
Isolate ID | Doubling time (hours) (95% CI) | Promastigote AmB-EC50 (µM) (95% CI) | Amastigote AmB-EC50 (µM) (95% CI) | AmB treatment rounds** | |||
|---|---|---|---|---|---|---|---|
M2903* | 8.826 | (8.440–9.249) | 0.03132 | (0.029–0.034) | 0.01005 | (0.0098–0.01032) | – |
A2 | 8.25 | (7.740–8.831) | 0.1094 | (0.097–0.119) | 0.01211 | (0.0117–0.0126) | 0 |
A8 | 9.831 | (9.277–10.46) | 0.05787 | (0.054–0.064) | 0.0226 | (0.0187–0.0274) | 0 |
A9 | 12.44 | (11.87–13.07) | 0.05329 | (0.047–0.060) | 0.02581 | (0.0243–0.0274) | 0 |
A10 | 7.019 | (6.275–7.965) | 0.1909 | (0.187–0.197) | 0.03263 | (0.0291–0.0366) | 0 |
A11 | 16.26 | (13.84–19.70) | 0.1363 | (0.108–0.173) | 0.008263 | (0.0035–0.0146) | 0 |
A18 | 7.779 | (7.266–8.370) | 0.04701 | (0.045–0.048) | 0.01488 | (0.0139–0.0159) | 0 |
A23 | 20.72 | (17.83–24.73) | 0.01876 | (0.013–0.023) | 0.007782 | (0.0071–0.0329) | 0 |
A26 | 13.52 | (10.97–17.63) | 0.04361 | (0.038–0.054) | 0.007306 | (0.0062–0.0085) | 0 |
A28 | 7.706 | (7.053–8.492) | 0.09162 | (0.086–0.094) | 0.2787 | (0.2610–0.2985) | 2 |
A36 | 16.35 | (15.35–17.49) | 0.163 | (0.140–0.167) | 0.1689 | (0.1371–0.2154) | 0 |
A42 | 9.995 | (9.690–10.32) | 0.08885 | (0.062–0.108) | 0.01816 | (0.0176–0.0188) | 0 |
A53 | 8.385 | (7.589–9.368) | 0.1136 | (0.091–0.138) | 0.01365 | (0.0117–0.0158) | 0 |
A66 | 8.385 | (7.589–9.368) | 0.2254 | (0.197–0.251) | 0.001374 | (1.9e-005-0.0144) | 3 |
